Telehealth Platform Improves HbA1c Levels For Rural Type 2 Diabetes Patients
The intervention model can be used to help manage a variety of chronic diseases.
Canagliflozin Use Reduces Total Heart Failure Events by 36%
Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.
Patients With Diabetes Need Psychological Care
Survey findings highlight the psychological and psychosocial distress related to having diabetes.
Closed-Loop Tech Improves Daytime Blood Sugar Control for Type 1 Diabetes
More patients achieve international time in range consensus target of greater than 70% with the Advanced system.
Ildiko Lingvay, MD: Predictors of Gastrointestinal Events with Semaglutide
A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.
Comparing Once-Weekly Semaglutide vs Daily Empagliflozin in Type 2 Diabetics
Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.
Meg Jardine, MBBS: Results and Impact of CREDENCE Results
After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.
Sam Engel, MD: Sitagliptin versus Dapagliflozin in Older Patients
A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.
Cardiovascular Impact of 10 Year Lifestyle Interventions In Diabetics
Osama Hamdy, MD, PhD, discusses the impact of a 10-year study observing the impact of lifestyle interventions among diabetes patients in real-world clinical practice.
Sam Engel, MD: Ertugliflozin Two-Year Impact on Renal Function
Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.
Ofri Mosenzon, MD: Dapagliflozin Impact on Renal Outcomes
A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.
Cardiovascular Risks Inflict Nearly Half of All Type 1 Diabetes Patients
A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.
Chris Sorli, MD: Renal Function on Toujeo versus Tresiba
A recent analysis of the BRIGHT trial examining renal function of insulin glargine 300u/mL versus insulin degludec 100u/mL was presented at ADA 2019.
Patrick Burgess, MD: Biggest Challenges Facing Diabetes Patients
After making the rounds at ADA 2019, Patrick Burgess, MD, discusses what he thinks is the most important discussion taking place at this year's conference and the biggest challenge facing diabetes patients.
Joanna Khatib, MD: Insulin Use Raises Risk of Severe Cardiovascular Events
An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.
Mahmood Kazemi, MD: Effectiveness of FreeStyle Libre for HbA1c Reduction
A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.
Sanjoy Paul, PhD: Depression, Antidepressant Use Among Diabetes Patients
A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.
Nicole Handlow: Impact of Multidisciplinary Team on Glycemic Control
Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.
Lindsay Clegg, PhD: Effects of SGLT2i with Exenatide on CV, Renal Outcomes
An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.
Teplizumab Halves Type 1 Diabetes Diagnoses in Phase 2 Trial
A new study from ADA showed the investigative monoclonal antibody suppressed development and diagnosis of T1D in at-risk patients.
Basal Insulin Has One-Year Window of Benefit Toward Glycemic Control
A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.
Trial Compares CV Outcomes in SGLT-2 Inhibitors Versus GLP-1 Agonists
Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.
New FIELD Study Assessment Links HDL Fractions to T2D Cardiovascular Risks
A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.
Patrick Burgess, MD: Hypoglycemia and Impact of Late Glucose Checks
A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.
Robert Busch, MD: Icosapent Ethyl for Diabetes Patients, REDUCE-IT Impact
A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.
Sue Kirkman, MD: Hurdles to Overcome in Diabetes Care
UNC professor of medicine discusses her thoughts on the largest challenges for physicians to overcome in the future of diabetes treatment.
Early Initiation of GLP-1RA/SGLT2 Lowers CV Risk, Increase HbA1C Control
Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.
Five-Year REWIND Results Show Sustained Dulaglutide CV Benefits
The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.
Cardiovascular Event Risks Similar in Type 1 & 2 Diabetes Patients
An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.
